Investors

Home  >  Investors  >  Overview

Why Invest

• Tetra is the only company in North America that is working with prescription drug regulators (i.e., Health Canada and FDA) to conduct rigorous clinical trials by bringing pharmaceutical science to the world of medicinal cannabis.

• As cannabis is a known entity for treating chronic pain, Tetra is able to bypass the long and extensive Phase II clinical trials with Health Canada and have expediency with the FDA.

• One of the emerging trend in the opioid market is smokable medical marijuana which Tetra plans to bring its lead product PPP001 – a smokable, natural medical marijuana to market for the treatment of chronic pain in cancer patients.

• While other global Pharmaceuticals have secured approval for cannabis derivatives, nobody has proven to regulators that smokable cannabis has any medical benefits.

• As the opioid epidemic affects millions in North America and continues to grow, there is an increasing demand for an alternative to opioids such as cannabis based drugs that will replace the toxic side effect profile of opioids.

•Tetra plans to develop a superior quality cannabinoid drug product through a scientific process which will create intellectual property which the company can protect via patents.

• In addition, Tetra plans on filing the IP for a device with a built-in mechanism for reducing drug abuse.

Events

There are currently no events scheduled.

Featured Presentation

Email Alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

* Required

*
*



 
Enter the code shown above.
UNSUBSCRIBE

Ir Contact

Edward Miller

Vice President,
IR & Corporate Communications
1 (514) 360-8040 ext. 203
edward@tetrabiopharma.com